JNJ-40411813   Click here for help

GtoPdb Ligand ID: 8946

Synonyms: ADX-71149 | ADX71149 | JNJ 40411813 | JNJ40411813
PDB Ligand
Compound class: Synthetic organic
Comment: JNJ-40411813 is a positive allosteric modulator (PAM) of the metabotropic glutamate receptor 2 (mGlu2) [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 25.24
Molecular weight 344.17
XLogP 6
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCCn1ccc(c(c1=O)Cl)N1CCC(CC1)c1ccccc1
Isomeric SMILES CCCCn1ccc(c(c1=O)Cl)N1CCC(CC1)c1ccccc1
InChI InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
InChI Key HYOGJHCDLQSAHX-UHFFFAOYSA-N
References
1. Cid JM, Tresadern G, Duvey G, Lütjens R, Finn T, Rocher JP, Poli S, Vega JA, de Lucas AI, Matesanz E et al.. (2014)
Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor.
J Med Chem, 57 (15): 6495-512. [PMID:25032784]
2. Lavreysen H, Ahnaou A, Drinkenburg W, Langlois X, Mackie C, Pype S, Lütjens R, Le Poul E, Trabanco AA, Nuñez JM. (2015)
Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor.
Pharmacol Res Perspect, 3 (1): e00096. [PMID:25692015]
3. Lavreysen H, Langlois X, Donck LV, Nuñez JM, Pype S, Lütjens R, Megens A. (2015)
Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813.
Pharmacol Res Perspect, 3 (2): e00097. [PMID:25692027]
4. Salih H, Anghelescu I, Kezic I, Sinha V, Hoeben E, Van Nueten L, De Smedt H, De Boer P. (2015)
Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies.
J Psychopharmacol (Oxford), 29 (4): 414-25. [PMID:25735992]